-
Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502
•
Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered into a licensing agreement with US based Acraris Therapeutics, Inc. (NASDAQ: ACRS). The deal grants Acraris exclusive global rights, excluding Greater China, to Biosion’s BSI-045B and BSI-502, further strengthening the two companies’ layout in the…
-
Biosion’s Bosakitug Shows Positive Results in Atopic Dermatitis Phase II POC Study
•
Biosion, a clinical-stage biotechnology company with operations in Delaware, U.S., and China, has announced key findings from its Phase II proof-of-concept (POC) ADAMANT study for bosakitug, a candidate in its pipeline for the treatment of atopic dermatitis (AD). Bosakitug is a monoclonal antibody (mAb) that targets thymic stromal lymphopoietin (TSLP),…
-
Biosion’s SIRPα-Targeting Monoclonal Antibody BSI-082 Clears US FDA Clinical Trial Hurdle
•
Biosion, a global clinical-stage biotechnology company dedicated to developing antibody-based therapies for immune and oncologic diseases, has announced that it has received clinical trial clearance from the US Food and Drug Administration (FDA) for its pipeline candidate BSI-082. This monoclonal antibody (mAb) targets SIRPα and is under development for the…
-
OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study
•
OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from the US Food and Drug Administration (FDA) to proceed with a Phase I/II study for its novel antibody drug conjugate (ADC) cancer therapy, OBI-992, which targets TROP2. The antibody molecules utilized in the development of…
-
Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline
•
Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic diseases, has successfully raised tens of millions of renminbi in a Series B+ financing round. The funds will be allocated to the development and advancement of the company’s innovative pipelines and to support its robust…
-
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B
•
Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases, has announced receiving approval from the US Food and Drug Administration (FDA) to initiate a Phase II clinical study for its thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) BSI-045B. The in-house developed BSI-045B is intended…
-
Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment
•
Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases, has announced the completion of a Series B financing round at upwards of RMB 100 million (USD 14.33 million). The funding was led by Guangfa Xinde Investment, with contributions from FangFund, Addor Capital, and Suxin…
-
Biosion and ImmunoGen Collaborate on Cancer ADCs
•
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with US firm ImmunoGen, Inc. (Nasdaq: IMGN). Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company, and ImmunoGen will provide…
-
Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials
•
China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval from the US FDA for its PYX-106 (BSI-060T). The anti-Siglec-15 monoclonal antibody (mAb) can now be assessed in clinics in bladder cancer, bile duct cancer, colorectal cancer, kidney cancer, and more. Preclinical Data and Drug…
